ICUHealthcare · BiotechnologyThe 1 Wall Street analysts covering Seastar Medical Holding Corp. hold a median 12-month price target of $10 — +198.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Seastar Medical Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ICU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +198.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Maxim Group | Maintains | Buy | $6.00 → $8.00 |
| 20 Apr 2023 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICU appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 80% of US stocks
Cheaper than 16% of US stocks
Cheaper than 32% of US stocks
Cheaper than 65% of US stocks
Higher than 91% of US stocks
Higher than 97% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 4% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Seastar Medical Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
SeaStar Medical Holding Corporation held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
Why it matters — Earnings call transcripts provide investors with direct insight into management's commentary on quarterly performance and strategic outlook.
SeaStar Medical announced its second quarter 2026 financial results and business updates. The company added three top-rated children's hospitals to its QUELIMMUNE pediatric acute kidney injury (AKI) customer base, driving net revenue up 82% versus the second quarter of 2025.
Why it matters — An ICU watcher would care because the expansion of QUELIMMUNE into more pediatric hospitals signals growing adoption of the therapy for AKI in critically ill children.
SeaStar Medical Holding Corporation announced that it will report its second quarter financial results after market close on Wednesday, August 12, 2026, and will host a webcast and conference call to discuss the results and business progress.
Why it matters — The scheduled earnings release and conference call give SeaStar Medical watchers a designated date to hear the company's latest financial results and business updates.
The 1 Wall Street analysts covering Seastar Medical Holding Corp. have a median 12-month price target of $10, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Seastar Medical Holding Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seastar Medical Holding Corp. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Seastar Medical Holding Corp. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +198.5% from the last close, and Ticker Nerd's factor model ranks Seastar Medical Holding Corp. 24 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Seastar Medical Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.
Seastar Medical Holding Corp. returned -58.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
SeaStar Medical Holding Corporation is a biotechnology company headquartered in Denver, Colorado, specializing in the development and commercialization of medical devices for critically ill patients. The company operates through its patented Selective Cytopheretic Device (SCD) technology platform, which is designed to address life-threatening conditions in acute care settings.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript". SeaStar Medical Holding Corporation held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
SeaStar Medical Holding Corporation is a biotechnology company headquartered in Denver, Colorado, specializing in the development and commercialization of medical devices for critically ill patients. The company operates through its patented Selective Cytopheretic Device (SCD) technology platform, which is designed to address life-threatening conditions in acute care settings. Its lead commercial product is QUELIMMUNE (SCD-PED) therapy, which received FDA approval under a Humanitarian Device Exemption for treating acute kidney injury due to sepsis in critically ill pediatric patients undergoing renal replacement therapy. The company focuses on bringing innovative therapeutic solutions to market within the surgical and medical instruments sector, serving healthcare providers and patients in need of advanced treatment options for severe acute conditions.
CEO Mr. Eric Schlorff · 18 employees · United States · https://seastarmedical.com